Healthcare provider profile · identity verified

Gregory Milani, M.D.

Family Practice · AURORA, IL · NPI 1356337836

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	634	168
Levothyroxine Sodium	Levothyroxine Sodium	291	63
Amlodipine Besylate	Amlodipine Besylate	277	70
Pravastatin Sodium	Pravastatin Sodium	277	75
Lisinopril	Lisinopril	229	57
Metformin Hcl	Metformin Hcl	216	59
Tamsulosin Hcl	Tamsulosin Hcl	182	49
Pantoprazole Sodium	Pantoprazole Sodium	165	55
Carvedilol	Carvedilol	137	36
Omeprazole	Omeprazole	134	33
Montelukast Sodium	Montelukast Sodium	128	31
Metoprolol Succinate	Metoprolol Succinate	126	45
Losartan Potassium	Losartan Potassium	121	37
Rosuvastatin Calcium	Rosuvastatin Calcium	120	36
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	117	28
Alprazolam	Alprazolam	106	27
Metformin Hcl Er	Metformin Hcl	101	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	94	20
Gabapentin	Gabapentin	90	22
Alendronate Sodium	Alendronate Sodium	85	25
Simvastatin	Simvastatin	83	20
Finasteride	Finasteride	81	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	24
Tramadol Hcl	Tramadol Hcl	77	24
Allopurinol	Allopurinol	73	23
Citalopram Hbr	Citalopram Hydrobromide	72	20
Donepezil Hcl	Donepezil Hcl	72	15
Hydrochlorothiazide	Hydrochlorothiazide	72	22
Jardiance	Empagliflozin	71	22
Sertraline Hcl	Sertraline Hcl	71	21
Potassium Chloride	Potassium Chloride	67	18
Trazodone Hcl	Trazodone Hcl	66	16
Pioglitazone Hcl	Pioglitazone Hcl	64	16
Duloxetine Hcl	Duloxetine Hcl	59	19
Clonazepam	Clonazepam	58	suppressed
Fluticasone Propionate	Fluticasone Propionate	52	19
Metoprolol Tartrate	Metoprolol Tartrate	52	15
Meloxicam	Meloxicam	49	16
Albuterol Sulfate Hfa	Albuterol Sulfate	48	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	12
Celecoxib	Celecoxib	46	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	45	12
Furosemide	Furosemide	44	18
Buspirone Hcl	Buspirone Hcl	42	suppressed
Solifenacin Succinate	Solifenacin Succinate	42	12
Clopidogrel	Clopidogrel Bisulfate	41	13
Bumetanide	Bumetanide	40	13
Zolpidem Tartrate	Zolpidem Tartrate	39	suppressed
Atenolol	Atenolol	34	suppressed
Famotidine	Famotidine	33	suppressed
Irbesartan	Irbesartan	33	suppressed
Lorazepam	Lorazepam	33	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Eliquis	Apixaban	32	suppressed
Glipizide Er	Glipizide	32	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Fenofibrate	Fenofibrate	30	suppressed
Mounjaro	Tirzepatide	30	suppressed
Ozempic	Semaglutide	30	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	29	suppressed
Pregabalin	Pregabalin	29	suppressed
Hydralazine Hcl	Hydralazine Hcl	28	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	26	suppressed
Mometasone Furoate	Mometasone Furoate	25	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Spironolactone	Spironolactone	24	suppressed
Topiramate	Topiramate	24	suppressed
Baclofen	Baclofen	23	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Azithromycin	Azithromycin	20	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Diazepam	Diazepam	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Primidone	Primidone	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	14	suppressed
Carisoprodol	Carisoprodol	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Glipizide	Glipizide	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Dantrolene Sodium	Dantrolene Sodium	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Lactulose	Lactulose	12	suppressed
Percocet	Oxycodone Hcl/Acetaminophen	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Adderall	Dextroamphetamine/Amphetamine	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Dutasteride	Dutasteride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error